A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Etoposide; Irinotecan
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors AB Science
- 01 Nov 2019 This trial has been withdrawn prior to enrolment in Slovakia as per European Clinical Trials Database
- 17 Jun 2019 This trial has been completed in France as per European Clinical Trials Database
- 18 May 2019 This trial has been completed in Spain, according to European Clinical Trials Database.